The 20 Best Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Doctors Near Me in Ann Arbor, MI

Stephen Goutman, MD, MS is an Associate Professor in the Department of Neurology and Director of the Amyotrophic Lateral Sclerosis Clinic and ALS Center of Excellence at Michigan Medicine. After obtaining a degree in neuroscience at the Johns Hopkins University (Baltimore, MD), Dr. Goutman completed his medical degree at the University of Chicago Pritzker School of Medicine (Chicago, IL) and his neurology residency and neuromuscular fellowship at Cleveland Clinic (Cleveland, OH). He received a Master’s in Clinical Research Design and Statistical Analysis at the University of Michigan (Ann Arbor, MI).Dr. Goutman evaluates and treats patients with neuromuscular diseases and is interested in diseases such as myasthenia gravis and muscle diseases. His area of expertise is amyotrophic lateral sclerosis (ALS)/Lou Gehrig’s Disease where his focus is delivering comprehensive and compassionate care. He is Director of the ALS Clinic, an ALS Association Certified Center of Excellence (http://www.umich-als.org/), where he leads a team of providers that care for persons with ALS and their families. Dr. Goutman is inspired by his patients and thus aims to provide the highest level of care.Dr. Goutman’s research is focused on identifying causes of and treatments for ALS. He leads research efforts that received funding by the National Institutes of Health and the Centers for Disease Control aimed at identifying environmental risk factors and causes of ALS (https://umhealthresearch.org/#studies/HUM00028826) and showed, in an article that received widespread attention, a connection between ALS and organochlorine pesticides (https://jamanetwork.com/journals/jamaneurology/fullarticle/2519875). Dr. Goutman also helps direct the University of Michigan ALS Biorepository which provides essential resources to ALS researchers within and external to the University of Michigan enabling studies into areas of ALS genetics, epigenetics, and immunology.Dr. Goutman is a site principal investigator of several multisite clinical trials focused on identifying new ALS treatments and causes and is an active participant with the Northeast ALS Consortium (NEALS) to improve care for ALS. He received a 2016 Young Investigator Award by the World Federation of Neurology Research Group on Motor Neuron Diseases. Dr. Goutman is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Spinal and Bulbar Muscular Atrophy. Dr. Goutman is board certified in Neurology, Neuromuscular Medicine, and Electrodiagnostic Medicine.

Dr. Feldman is the director of the NeuroNetwork for Emerging Therapies at Michigan Medicine and the ALS Center of Excellence at Michigan Medicine. The latter includes the Pranger ALS Clinic, one of the top multidisciplinary clinics caring for those suffering from amyotrophic lateral sclerosis (ALS). She serves as the University of Michigan James W. Albers Distinguished University Professor and the Russell N. DeJong Professor of Neurology at Michigan Medicine. Dr. Feldman is one of the world’s leading authorities on neurodegenerative disease.Dr. Feldman is a compassionate and dedicated physician who cares deeply about her patients. She has been recognized for her clinical excellence by numerous organizations and is annually named as one of the “Best Doctors in America.” Her forward-thinking, collaborative, multidisciplinary approach has transformed how neurodegenerative diseases are diagnosed, treated, and prevented.Dr. Feldman has made significant contributions to biomedical research and clinical care in many critical areas of neurodegenerative disease. She has authored over 530 peer-reviewed publications, 74 book chapters, and 5 books on the pathology, diagnosis, and treatment of neurological diseases. Dr. Feldman has been continuously funded by the NIH since 1989 and is currently the principal or co-investigator of numerous clinical trials and grants. She has received numerous awards and honors throughout her remarkable career, including the University of Michigan’s Early Distinguished Career Award, the Distinguished Faculty Achievement Award, and the Distinguished Alumnus Achievement Award. She was also the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. In 2022, Dr. Feldman was awarded the University of Michigan Distinguished Professorship, the highest faculty honor at University of Michigan.Dr. Feldman is actively committed to and involved in professional service. She served as President of the Peripheral Nerve Society from 2007-2009 and President of the American Neurological Association (ANA) from 2011-2013. Dr. Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. Dr. Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology, Nature Reviews Neurology, JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry. Dr. Feldman is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Peripheral Neuropathy, Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Autonomic Neuropathy. Dr. Feldman is board certified in Neurology and Electrodiagnostic Medicine.

Sami Barmada, M.D., Ph.D. is an assistant professor of neurology at the University of Michigan Medical School. His clinical interests center around patients with dementia and motor neuron disease, and he sees patients at the Cognitive Disorders Clinic in the University of Michigan’s East Ann Arbor location.His research focuses on the pathologic overlap between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and how we can take advantage of the convergence to identify new and effective therapies for these devastating disorders.After graduating from the University of Pittsburgh, Pennsylvania, in 1998 with a major in Molecular Biology, Biochemistry, and a focus in Conceptual Foundations of Medicine, Dr. Barmada went on to the Medical Scientist Training Program at Washington University in St. Louis School of Medicine. For his graduate work, he constructed a transgenic mouse model of Creutzfeldt-Jacob disease with Dr. David Harris, and used these animals to track the deposition of misfolded prion protein within the nervous system of infected animals. For this work, Dr. Barmada earned earned the Poletsky Award from the Alzheimer’s Disease Research Center in St. Louis, Missouri, and was elected as a Olin Medical Scientist Fellow at Washington University School of Medicine.Dr. Barmada received his M.D. and Ph.D. in 2006, and completed an Internal Medicine internship at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, before moving to the University of California, San Francisco (UCSF), Medical Center for his residency in Neurology. Dr. Barmada served one year as Chief Resident in the Department of Neurology, focusing on resident education. He was also a house-staff nominee to the Alpha-Omega-Alpha honor society. During his residency, Dr. Barmada became involved in research with Dr. Steve Finkbeiner of the Gladstone Institutes, a pioneer in neuronal models of neurodegenerative disease and novel technologies to study these models. Dr. Barmada finished his residency in 2010 and spent one year working with Dr. Finkbeiner as a research fellow, before becoming a Staff Scientist at the Gladstone Institutes and a Clinical Instructor at UCSF. In 2013, Dr. Barmada became an Assistant Professor of Neurology at the University of Michigan, where he divides his time between the Cognitive Disorders Clinic and the laboratory. Dr. Barmada is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Frontotemporal Dementia, and Dementia. Dr. Barmada is board certified in Neurology.

Dr. Callaghan completed his medical degree and neurology residency at the University of Pennsylvania. He completed a fellowship in neuromuscular disease at the University of Michigan. He also completed a master's degree program in clinical research at the University of Michigan School of Public health. Dr. Callaghan is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Peripheral Neuropathy, Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Thrombectomy, and Thymectomy. Dr. Callaghan is board certified in Neurology.

Peter K. Todd, M.D., Ph.D., is an assistant professor in the Department of Neurology in the University of Michigan Medical School.Dr. Todd earned his Bachelor of Science degree in 1994 from the University of California, San Diego. He then entered the Medical Science Training Program at the University of Wisconsin at Madison, where he completed his doctorate in 2002 and medical degree in 2004. His Ph.D research focused on synaptic defects in Fragile X Syndrome, a common inherited cause of cognitive impairment in children.He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While there, he did research on the role of the ubiquitin proteasome system and autophagy in Spinal and Bulbar Muscular Atrophy, a polyglutamine disorder, and Fragile X Tremor Ataxia Syndrome (FXTAS). He came to the U-M in 2008 for a clinical and research fellowship in movement disorders and neurogenetics.Todd joined the U-M faculty in 2010 as an assistant professor in movement disorders and neurogenetics, working in the laboratory of Henry L. Paulson, M.D., Ph.D., in the Center for Neurodegenerative Research.His current research is focused on the mechanisms underlying RNA-mediated neurodegeneration in FXTAS and myotonic dystrophy, and how these mechanisms may overlap and inform our understanding of other neurodegenerative disorders. He also sees patients with movement disorders and inherited neurological disease.Dr. Todd has received several academic awards, including a Howard Hughes Undergraduate Research Fellowship, the Francis M. Forester Prize for promise as an academic neurologist, the Samuel Ziritzky Prize for most outstanding research by a neurology resident at Penn and prizes for excellence in research at the International Conference on Unstable Microsatellites in Human Disease, and the U-M neuroscience day. Most recently, Dr Todd received the S. Weir Mitchell Alliance award from the American Academy of Neurology which each year recognizes one early investigator physician scientist who has made important contributions to basic science in neurological disorders.A member of the American Medical Association and the American Academy of Neurology, he has served as an ad-hoc reviewer for the Journal of Biological Chemistry, Neurology, Proceedings of the National Academy of Sciences, Neuron, Science and Human Molecular Genetics.His bibliography includes several peer-reviewed papers, editorials, book reviews and chapters, abstracts and online. Dr. Todd is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Fragile X Syndrome, Fragile XE Syndrome, Hereditary Ataxia, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Dr. Todd is board certified in Neurology.

Dr. Schmidt attended medical school at Michigan State University, and completed her residency training in PM&R at the University of Pittsburgh Medical Center where she also served as chief resident. Dr. Schmidt's clinical responsibilities include outpatient practice focusing on transition into adulthood for pediatric patients with disabilities, cerebral palsy, amyotrophic lateral sclerosis and other neuromuscular conditions. Dr. Schmidt is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). She is also highly rated in 49 other conditions, according to our data. Her clinical expertise encompasses Dysferlinopathy, Spinal Muscular Atrophy (SMA), Spinal Muscular Atrophy Type 3, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

After graduating from Tehran University of Medical Sciences in 1990, Dr. Sohrab spent time in Spinal Cord Injury Centers of Iran, in multiple capacities, organizing care and educating different levels of practitioners in providing care for veterans of war. He then spent a few years of general practice, in different parts of Iran, dedicated to providing medical care and organizing Public Health Services, in rural areas. Dr. Sohrab has been practicing, and teaching, general Neurology at the University of Michigan, since 2012. Dr. Sohrab is rated as an Experienced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Migraine, Vertigo, Migraine with Brainstem Aura, and Trigeminal Neuralgia.

Ann Little is a Neurologist and a Neuroradiologist practicing medicine in Ann Arbor, Michigan. Dr. Little is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). She is also highly rated in 63 other conditions, according to our data. Her clinical expertise encompasses Inclusion Body Myositis, Polymyositis, Myasthenia Gravis, Stent Placement, and Transmyocardial Revascularization.

John K. Fink, MD, is a professor in the Department of Neurology and director of the Neurogenetic Disorders Program in the University of Michigan Medical School. He directs basic science laboratory research focused on identifying genes and mechanisms responsible for age-dependent neurologic degeneration; and on developing treatments for these conditions.Fink's laboratory investigates the molecular basis of inherited neurologic and psychiatric disorders. His clinical expertise focuses on inherited and degenerative disorders of the nervous system. Dr. Fink evaluates individuals of all ages, from infancy through senescence with these disorders, which include lysosomal storage disorders (such as Gaucher disease, Niemann-Pick disease and Fabry disease), ataxias (including Friedreich's ataxia), leukodystrophies (such as Krabbe, CADASIL and adrenoleukodystrophy), familial dystonia, primary lateral sclerosis, Wilson's disease, familial motor neuron disease (including familial amyotrophic lateral sclerosis), familial dementia, and a group of inherited spinal cord disorders known collectively as the Hereditary Spastic Paraplegias (HSPs).Dr. Fink came to the University of Michigan in 1990 as an assistant professor of neurology and director of the Neurogenetic Disorders Clinic. The program provides care and evaluation for individuals and families with inherited and degenerative neurologic disorders; and clinical and molecular laboratory training for physicians and scientists studying these disorders. He was promoted to associate professor in 1996 and professor in 2005.Board-certified in neurology and medical genetics, Dr. Fink received his medical degree in 1980 from the Medical College of Ohio in Toledo. Following internship at the Mayo Clinic in Rochester, Minnesota, he completed a neurology residency in 1984 at the University of Virginia in Charlottesville. Subsequently, he trained in developmental and metabolic neurology and medical genetics at the National Institutes of Health.Dr. Fink has served as the Medical Advisor to the Spastic Paraplegia Foundation since its establishment (2002), and serves as ad hoc reviewer for numerous journals and NIH study sections.A member of the American Society of Human Genetics, American Academy of Neurology, American Neurological Association and the American College of Genetics, Dr. Fink received the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association in 2002. In addition, he has been elected by peers to Best Doctors in America annually since 2001. Dr. Fink is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 45 other conditions, according to our data. His clinical expertise encompasses Spastic Paraplegia Type 7, Spastic Paraplegia Type 2, Primary Lateral Sclerosis, and CACH Syndrome. Dr. Fink is board certified in Clinical Genetics and Neurology.

Savannah Quigley is a Neurologist and a Neuromusculoskeletal Medicine provider practicing medicine in Ann Arbor, Michigan. Dr. Quigley is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Dr. Quigley is board certified in Neurology and Neuromuscular Medicine.

Henry L. Paulson, M.D., Ph.D., is the Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan. Dr. Paulson joined the U-M faculty in 2007, and he currently directs the Michigan Alzheimer’s Disease Center (MADC) and co-direct the U-M Protein Folding Diseases Initiative.Dr. Paulson received his medical degree and doctorate in Cell Biology from Yale University in 1990. He then completed a neurology residency and neurogenetics/movement disorders fellowships at the University of Pennsylvania. In 1997, he joined the Neurology faculty at the University of Iowa, where he remained until 2007.Dr. Paulson's research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on polyglutamine diseases, Alzheimer's disease and frontotemporal dementia. In 1997, his lab described abnormal protein aggregates in the polyglutamine diseases, which now are recognized as a pathological hallmark in this important class of inherited diseases. Using test tube, cell-based and animal models, he has contributed to advances in the understanding of various neurodegenerative diseases. His lab also has helped pioneer the use of gene silencing methods as potential therapy for the many neurological disorders caused by toxic mutant genes.Nationally, Dr. Paulson has directed popular courses at the American Academy of Neurology meetings, serves on the scientific advisory boards of numerous disease-related national organizations, and is past Chair of the Board of Scientific Counselors at the National Institute for Neurological Disorders and Stroke at the National Institutes of Health.Among his awards, Dr. Paulson is an Ellison Medical Foundation New Scholar in Aging, a semifinalist for the W.M. Keck Foundation Young Scholars in Medical Research, and a recipient of the Paul Beeson Physician Faculty Scholar in Aging Award from the American Federation for Aging Research. Dr. Paulson is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 3, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology.

Dr. Rodriguez is Medical Director of the Wheelchair Seating Clinic and PM&R Administrator in the Michigan Bowel Control Clinic and the Wound Care Clinic. She has been actively involved in research with the Spinal Cord Injury Model System. She has written and collaborated on several research publications and written chapters on SCI sequelae in premier journals and textbooks in PM&R. Dr. Rodriguez has been recognized for her teaching of trainees with the Silver Crutch award. She is the associate SCI fellowship program director. She also serves on the International Standards and Autonomic Standards Committees, two crucial committees of the American Spinal Injury Association that are responsible for development of any new standards documents related to SCI, continuous review and improvement of the existing ASIA documents on neurological and autonomic standards and development and oversight of the International Data Sets project. Dr. Rodriguez is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). She is also highly rated in 43 other conditions, according to our data. Her clinical expertise encompasses Neurogenic Bowel, Paraplegia, Spasticity, and Autonomic Dysreflexia.

Gary Gallagher, MD completed his undergraduate bachelor of science degree in Industrial and Operations Engineering at the University of Michigan. An interest in health sciences, lead him to attend medical school at Wayne State University of Medicine in Detroit, MI where he received his doctorate of medicine in 2008. He completed residency in neurology and fellowship in neuromuscular medicine at the University of Michigan. During final year of residency, he served as chief resident. Following completion of fellowship, Dr. Gallagher joined the neurology faculty at the University of Michigan.Dr. Gallagher is interested in the clinical care of neuromuscular disease, tele-medicine, electrodiagnostic procedures (EMG and intraoperative monitoring). His clinical time is spent in the outpatient neuromuscular clinic providing longitudinal care for patients and on the inpatient service caring for acute neurologic problems including stroke management, epilepsy, neuromuscular crisis and auto-immune neurologic disease. In addition, he has strong interest in medical trainee education and he serves as the neuromuscular fellowship director at the University of Michigan. Finally, Dr. Gallagher has strong interest in patient safety and quality improvement and oversees departmental efforts to improve. Dr. Gallagher is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 71 other conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Multifocal Motor Neuropathy, Inclusion Body Myositis, and Peripheral Neuropathy.

Dr. Erika Weil completed her undergraduate studies at Purdue University where she studied Neurobiology and physiology. She attended medical school at Indiana University School of Medicine. She then completed Neurology residency, chief residency and fellowship training in Vascular Neurology at Mayo Clinic, Rochester, MN. She completed an additional fellowship training in neuroimaging at Houston Methodist Hospital. Dr. Weil is rated as an Experienced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Stroke, Dysarthria, Hemiplegia, Stent Placement, and Transmyocardial Revascularization. Dr. Weil is board certified in Neurology.

Alan D. Salgado, M.D. is an assistant professor in the Department of Neurology in the University of Michigan Medical School.Dr. Salgado grew up in Gainesville, Florida. He graduated Summa Cum Laude from the University of Florida in 2011. Prior to attending medical school, he completed a postbaccalaureate research training fellowship at the National Institutes of Health. In 2016 he graduated from the University of Florida College of Medicine. He completed a preliminary medicine internship at MedStar Georgetown University Hospital, followed by neurology residency at Vanderbilt University Medical Center. He further completed a fellowship in neuromuscular medicine and EMG at Duke University Medical Center.Dr. Salgado joined the neurology faculty at the University of Michigan in 2022. Dr. Salgado is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Spinal Muscular Atrophy Type 3, Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Thrombectomy. Dr. Salgado is board certified in Neurology, Neuromuscular Medicine, and Electrodiagnostic Medicine.

Dr. Praveen Dayalu is an Associate Professor and the Thomas H. and Susan C. Brown Early Career Professor of Neurology at the University of Michigan. He graduated from medical school at Case Western Reserve University in Cleveland, in 2002, and then completed neurology residency and movement disorders fellowship at Michigan, in 2006. His main focus is clinical management of movement disorders, especially Parkinson disease. His research interests are in Huntington disease and Multiple System Atrophy. He is the Director of the Movement Disorders Fellowship and trains fellows, residents, and medical students. Dr. Dayalu is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Huntington Disease, Movement Disorders, Drug Induced Dyskinesia, and Parkinson's Disease. Dr. Dayalu is board certified in Neurology.

Zach London, M.D. is a Professor in the University of Michigan Medical School. Dr. London grew up in Milwaukee, Wisconsin. He graduated Magna Cum Laude from Brown University in 1997. He attended medical school at the University of Wisconsin – Madison, graduating in 2001. He completed a Preliminary Medicine Internship at St. Joseph Mercy Hospital in Ann Arbor in 2001, followed by Neurology Residency at the University of Michigan. After graduation from residency, he did a one-year fellowship in Clinical Neurophysiology/EMG at the University of Michigan.He joined the University of Michigan faculty as a neuromuscular neurologist in 2006, and has served as Program Director of the neurology residency program. Dr. London’s scholarly focus is the development of interactive educational tools, with a focus on educational boardgames. He is the founder of Neurd Games, which includes popular titles such as The Lesion: Charcot’s Tournament, The Plexus, Endowed Chairs: Neurology, Formaina, and Field Cut. He also created EMG Whiz, a popular web-based EMG training simulator, and mobile applications to teach the tenets of neuroanatomic localization.He has published online learning modules for the American Academy of Neurology and other national organizations, in addition to traditional publishing research regarding medical education and electrodiagnostic studies.Dr. London has been recognized with numerous national teaching awards, including the American Academy of Neurology (AAN) A.B. Baker Lifetime Achievement Award in Neurologic Education in 2023, The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Innovation Award in 2021, and the American Neurological Association (ANA) Distinguished Teacher Award in 2017. At the University of Michigan, he received the 2013 Silver Shovel Award, the Provost’s Teaching Innovation Prize in 2015, and, in 2017, the Kaiser Permanente Award. Departmental honors include the Status Pedagogicus Award in 2008, and the James Albers Collegiate Professorship in 2018. He has been an honorary member of the GALENS medical society most years since 2011. Dr. London regularly speaks at national meetings on topics of medical education, game development, and clinical neurophysiology. He has served as chair or member of committees and workgroups for the AAN, ANA, AANEM, and ACGME, including serving as the Chair of the Consortium of Neurology Program Directors.Outside his work, Zach London is a founding board member of the Penny Seats Theatre Company in Ann Arbor. He has also composed and released one original song every month since 1993, posting them on his personal website www.hardtaco.org. Dr. London is rated as an Experienced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyneuropathy, and Chronic Polyradiculoneuritis. Dr. London is board certified in Neuromuscular Medicine, Neurology, and Electrodiagnostic Medicine.

Craig Williamson is a Neurologist and a Neurosurgery provider practicing medicine in Ann Arbor, Michigan. He has been practicing medicine for over 17 years. Dr. Williamson is rated as an Experienced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Subdural Hematoma, Subarachnoid Hemorrhage, Increased Intracranial Pressure, Thrombectomy, and Stent Placement. Dr. Williamson is board certified in Neurology and Neurocritical Care.

Dr. Elafros graduated Phi Beta Kappa and with honors from Michigan State University in Human Biology and Spanish before completing a Masters of Arts in Bioethics. She then received her MD degree and PhD in Epidemiology from Michigan State University during which time she lived in Zambia for two years to complete her doctoral dissertation which examined the medical and psychosocial burden of HIV and epilepsy among adults in the capital city Lusaka. Dr. Elafros then completed a neurology residency at Johns Hopkins Hospitals, during which time she received an R25 from the National Institutes of Health which allowed her to return to Zambia to examine barriers to care for patients with meningitis. She then joined the University of Michigan for neuromuscular fellowship in 2020.Dr. Elafros provides longitudinal patient care through the outpatient neuromuscular clinic at the University of Michigan. Dr. Elafros is rated as an Experienced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Peripheral Neuropathy, Diabetic Neuropathy, Myasthenia Gravis, and Seizures. Dr. Elafros is board certified in Neurology and Electrodiagnostic Medicine.

Dr. Teresa Jacobs is the director of the Neurological Intensive Care Unit (NICU). Dr. Jacobs attended Medical School at the University of Pittsburgh and then did her residency in Neurology at the University of Virginia. She also completed a fellowship in Critical Care Medicine at the University of Virginia. Dr. Jacobs joined the University of Michigan in 2005. As a neurointensivist, Dr. Jacobs cares for any neurosurgical patients who require critical care after their surgeries. Dr. Jacobs is rated as an Experienced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Her clinical expertise encompasses Subarachnoid Hemorrhage, Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Stent Placement, and Transmyocardial Revascularization.